Announcement on Abnormal Stock Trading Fluctuations

Securities Code: 002432 Securities Abbreviation: Ninehealth Medical Announcement No.: 2026-045

Tianjin Ninehealth Medical Electronic Co., Ltd.

Announcement on Abnormal Stock Trading Fluctuations

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Key Content Highlights:

1. The stock of Tianjin Ninehealth Medical Electronic Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") experienced cumulative closing price deviation exceeding 20% on July 15, 2026, and July 16, 2026, for two consecutive trading days. According to the relevant regulations of the "Trading Rules of Shenzhen Stock Exchange," this constitutes abnormal stock trading fluctuations. The Company's recent fundamentals have not undergone significant changes. The Company's stock price has experienced significant fluctuations due to market sentiment, concept speculation, and other factors, and there is a risk of future stock price volatility and decline.

2. The Company's innovation investments do not have principal protection or minimum return guarantees. The investment targets are easily affected by market changes in their respective industries, industry policy regulations, and other factors, which may affect their valuation. There is a risk of investment failure and loss. Innovation investments are characterized by long investment recovery periods and low liquidity. The investment process may be affected by various factors such as macroeconomic conditions, industry cycles, market competition, policy environment, and the operating management of the proposed investment projects, and future returns are uncertain.

3. The Company disclosed the "2026 Half-Year Performance Forecast" (Announcement No.: 2026-042) on July 15, 2026. It is estimated that the net profit attributable to shareholders of the listed company for the first half of 2026 will be between RMB 2.8 billion and RMB 3.4 billion. This is mainly due to the emerging returns from the Company's strategic investments in innovation. The underlying assets' valuation increased during the reporting period, positively impacting the Company's performance. Innovation investments do not have principal protection or minimum return guarantees. The valuation fluctuations of the invested assets are affected by market factors and are highly uncertain. The aforementioned performance forecast does not currently require revision. The data in this performance forecast is the preliminary calculation result of the Company's finance department and may differ from the 2026 half-year report to be disclosed. The specific financial data will be subject to the 2026 half-year report disclosed by the Company. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

4. The Company's wholly-owned subsidiary, Andon Hong Kong Co., Limited (hereinafter referred to as "Ninehealth Hong Kong"), indirectly invested in Hangzhou DeepSeeker AI Foundation Technology Research Co., Ltd. (hereinafter referred to as the "Target Company") through Tianjin Shixiang Investment Partnership (Limited Partnership). Ninehealth Hong Kong's investment amount was RMB 750 million.